T45.AX5A Insurance Policy Changes

ICD-10 T45.AX5A is officially defined as "Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter." code T45.AX5A is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code T45.AX5A is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 17, 2026Medium impact
Adalimumab (CPB 0655, reviewed 2026-07-13)
Aetna's clinical policy bulletin 0655 sets the coverage rules for adalimumab (Humira) and its biosimilars under commercial medical plans. Adalimumab is considered medically necessary for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, non-infectious uveitis, Behcet's disease, pyoderma gangrenosum and immune checkpoint inhibitor-related inflammatory arthritis when the listed criteria are met. The policy also states that Hulio has been discontinued as of 1/1/2026, and that adalimumab-fkjp is the unbranded generic of Hulio.
Aetna · Identified Aug 16, 2026Medium impact
Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)
Aetna covers siltuximab (Sylvant) for commercial medical plans when it is used for multicentric Castleman's disease that is HIV-1 negative and HHV-8 negative, for relapsed, refractory or progressive unresectable unicentric Castleman's disease that is HIV-1 negative and HHV-8 negative, and for specific cytokine release syndrome cases, including grade 4 CAR T-cell-induced cytokine release syndrome that is refractory to high-dose corticosteroids and anti-IL-6 therapy. Continuation of therapy is covered when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. Aetna considers all other indications experimental, investigational, or unproven, including breast cancer, multiple myeloma, rheumatoid arthritis and COVID-19.
Aetna · Identified Aug 15, 2026Medium impact
Golimumab (Simponi and Simponi Aria) (CPB 0790, reviewed 2026-07-31)
Golimumab is covered for commercial plans when the criteria for the requested form and indication are met. Intravenous Simponi Aria is covered for moderately to severely active rheumatoid arthritis given with methotrexate, active psoriatic arthritis, active ankylosing spondylitis, articular juvenile idiopathic arthritis in members 2 years of age or older, and moderate or severe immune checkpoint inhibitor-related inflammatory arthritis. Subcutaneous Simponi is covered for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, moderately to severely active ulcerative colitis, and immune checkpoint inhibitor-related inflammatory arthritis. Concomitant use with another biologic or targeted synthetic drug for the same indication is considered experimental, investigational or unproven, as are Behcet's disease, Crohn's disease, non-infectious uveitis, panuveitis, posterior uveitis and scleritis for intravenous golimumab, plus asthma and sarcoidosis for subcutaneous golimumab.
Aetna · Identified Aug 13, 2026Medium impact
Etanercept (CPB 0315, reviewed 2026-07-08)
Aetna's Clinical Policy Bulletin 0315 considers etanercept (Enbrel) medically necessary for rheumatoid arthritis, articular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, reactive arthritis, hidradenitis suppurativa, graft versus host disease, Behcet's disease and immune checkpoint inhibitor-related toxicity when the listed criteria are met. Initial criteria differ by indication and include prior treatment with other drugs for several of them, and continuation of therapy requires a positive clinical response. Aetna considers all other indications experimental, investigational, or unproven, including concomitant use with another biologic or targeted synthetic drug for the same indication.

Watch T45.AX5A

Get one email when a payer policy names T45.AX5A, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code T45.AX5A?

There are 4 tracked policy changes affecting code T45.AX5A, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code T45.AX5A?

Payers that have issued tracked updates for code T45.AX5A include: Aetna.

How do I get notified when code T45.AX5A policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code T45.AX5A. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code T45.AX5A?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Adalimumab (CPB 0655, reviewed 2026-07-13)

Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)

Golimumab (Simponi and Simponi Aria) (CPB 0790, reviewed 2026-07-31)

Etanercept (CPB 0315, reviewed 2026-07-08)

What insurance policy changes affect code T45.AX5A?

Which payers have updated policy for code T45.AX5A?

How do I get notified when code T45.AX5A policy changes?

Why do payers change policies for code T45.AX5A?